Table 1.
Summary of patient characteristics.
| Patient characteristics | Overall (n = 18) |
|---|---|
| Gender, numbers (%) | |
| Female | 9 (50) |
| Male | 9 (50) |
| Age at start of lorlatinib therapy, median (range), y | 5.7 (2.1–39.1) |
| N-MYC status, numbers (%) | |
| Amplified | 8 (44) |
| Nonamplified | 10 (56) |
| Number of previous relapse/progression, median (range) | 2 (1–6) |
| Type of ALK alteration | |
| Mutation | |
| F1174L | 7 (39) |
| R1275Q | 3 (17) |
| F1245C | 1 (6) |
| F1245I | 1 (6) |
| I1170N | 1 (6) |
| R1278 + Y1278 | 1 (6) |
| F1174L + F1245I + R1275Q | 1 (6) |
| F1174S + R1275Q | 1 (6) |
| Amplification | 1 (6) |
| Rearrangement | 1 (6) |
| Administered lorlatinib/lorlatinib + chemotherapy cycles, numbers | 155 |
| Median (range) | 4 (1–8) |